ConcertAI is an AI-driven platform that utilizes real-world data and advanced analytics to enhance clinical trial design and execution in oncology. The company addresses the inefficiencies in cancer research by providing biopharma partners with actionable insights to accelerate drug development and improve patient outcomes.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional clinical trial designs in oncology often suffer from inefficiencies, leading to prolonged drug development timelines and delayed access to potentially life-saving treatments for cancer patients. The complexities of cancer research and the heterogeneity of patient populations further exacerbate these challenges.
Solution
ConcertAI offers an AI-powered platform that leverages real-world data (RWD) and advanced analytics to optimize clinical trial design and execution in oncology. By integrating diverse data sources, including EMR systems and genomic data, ConcertAI provides biopharma companies with actionable insights to accelerate drug development. The platform facilitates improved patient outcomes through enhanced trial data analysis, novel data techniques for various study designs, and solutions to increase patient adherence. ConcertAI's approach aims to streamline the clinical trial process, enabling faster and more effective development of cancer therapies.
Target Audience
The primary target audience includes biopharmaceutical companies, clinical research organizations, and healthcare providers involved in oncology drug development and patient care.
Features
- Access to a large U.S. oncology RWD, incorporating data from numerous EMR systems, medical oncologists, and provider cancer clinics, with frequent data refreshes.
- AI models for accelerating trial data analysis and implementing novel data and analytics techniques for RCTs, pragmatic trials, external controls, or adaptive studies.
- Integration of TeraRecon's medical imaging technology for advanced visualization and AI-driven diagnostics.
- Clinical development solutions for various cancer types, including AML, bladder, breast, gastric-esophageal, liver, lung, melanoma, multiple myeloma, pancreatic, prostate, and renal cancers.
- Commercial solutions to drive better patient outcomes across a range of diseases, including AML, breast cancer, cirrhosis, Fabry disease, GIST, hemophilia, Hepatitis C, leukemia, multiple sclerosis, myelofibrosis, plaque psoriasis, prostate cancer, pulmonary arterial hypertension, rheumatoid arthritis, schizophrenia, and tardive dyskinesia.
- CancerLinQ integration for real-world data insights in oncology care.